EPA-Approved Pesticide Labels as “Requirements” Under FIFRA: Express Preemption of State Failure-to-Warn Cancer Claims

1. Introduction

Monsanto Co. v. Durnell addresses the recurring conflict between federal pesticide labeling regulation and state tort duties. Monsanto manufactures Roundup, a glyphosate-based herbicide. The Environmental Protection Agency (EPA) has repeatedly evaluated glyphosate and repeatedly concluded it is “not likely to cause cancer,” and EPA has not required a cancer warning on glyphosate-based pesticide labels.

John Durnell sued Monsanto in Missouri state court alleging Roundup caused his non-Hodgkin’s lymphoma and, relevant here, that Monsanto failed to warn by omitting a cancer warning on Roundup’s label. A jury awarded damages and the Missouri Court of Appeals affirmed (707 S. W. 3d 828).

The Supreme Court granted certiorari to resolve a split among courts on whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts Roundup cancer-warning failure-to-warn suits. The Court reversed, holding the claim preempted by 7 U. S. C. §136v(b).

2. Summary of the Opinion

Justice Kavanaugh, for the Court, holds that FIFRA’s express preemption clause (“Uniformity”) bars Durnell’s state-law failure-to-warn claim because it would impose a labeling requirement “in addition to or different from” federal requirements “under” FIFRA.

• EPA registration requires EPA approval of the pesticide label, including determination that the label contains all warnings “necessary and . . . adequate to protect health and the environment” and contains no “false or misleading” statements. See 7 U. S. C. §§136a(c)(5)(B), 136(q)(1)(A), (G).
• After approval, manufacturers are legally required to use the EPA-approved label unless and until EPA approves or requires a change. See §136a(f)(1); 40 CFR §§152.44(a), 156.70(c).
• State tort duties are “requirements” for labeling; thus a state failure-to-warn verdict requiring a cancer warning is an additional/different labeling requirement. See Bates v. Dow Agrosciences LLC, 544 U. S. 431, 443-444.
• The Court finds confirmation in Riegel v. Medtronic, Inc., 552 U. S. 312, which treated FDA premarket approval as imposing federal “requirements” that preempt additional/different state-law duties under materially similar preemption language.

3. Analysis

A. Precedents Cited (and how they shaped the outcome)

1) Bates v. Dow Agrosciences LLC, 544 U. S. 431 (2005)

Bates is the Court’s principal FIFRA preemption precedent. The majority extracts two propositions: (1) state common-law duties, including failure-to-warn duties, qualify as state “requirements” for labeling; and (2) the relevant federal “requirements” include FIFRA’s misbranding standards and “any relevant EPA regulations that give content to FIFRA’s misbranding standards.”

The Court uses Bates to anchor the key interpretive move: once state tort duties count as “requirements,” a tort rule compelling a label change can trigger §136v(b). The majority also reads Bates as distinguishing between non-preempted claims (there, efficacy-related claims said to fall outside EPA’s registration review) and preempted claims (here, safety warnings, which EPA reviews “thoroughly” at registration).

The dissent (Jackson, J.) reads Bates very differently, emphasizing its endorsement of “parallel” state claims that “merely duplicate federal requirements.” The majority rejects that framing by treating EPA’s registration/label-approval determinations themselves as federal requirements “under” FIFRA that Durnell’s verdict would contradict.

2) Riegel v. Medtronic, Inc., 552 U. S. 312 (2008)

Riegel supplies the majority’s strongest analogy: where a federal agency’s premarket approval locks in labeling/content obligations, that approval process can create enforceable federal “requirements” for preemption purposes. Because the Medical Device Amendments’ clause is “nearly identical” to FIFRA’s, Riegel is treated as effectively “dispositive” on the sub-question whether an agency approval regime can generate preemptive “requirements.”

The dissent attempts to distinguish Riegel based on FIFRA’s §136a(f)(2) and the availability of “parallel claims,” but the majority answers that §136a(f)(2) does not negate the preemptive effect of EPA’s specific determination that no cancer warning is required and that Riegel is not undermined by the possibility of later agency reconsideration.

3) Cipollone v. Liggett Group, Inc., 505 U. S. 504 (1992)

Cited for the broader proposition that state common-law duties can constitute “requirements” for preemption analysis, reinforcing Bates and supporting the threshold step that a Missouri failure-to-warn duty is a labeling requirement.

4) Wisconsin Public Intervenor v. Mortier, 501 U. S. 597 (1991)

Used as historical and structural context: the 1972 amendments transformed FIFRA into a “comprehensive regulatory statute” and strengthened EPA’s central role. That broader regulatory structure supports the majority’s emphasis on uniformity and EPA’s “central and comprehensive” labeling determinations.

5) Landgraf v. USI Film Products, 511 U. S. 244 (1994)

Not a preemption precedent here but invoked to illuminate fairness/retroactivity concerns: the majority notes the anomalous consequences of imposing tort liability for failure to do something federal law allegedly forbade (unilaterally changing the label).

6) Loper Bright Enterprises v. Raimondo, 603 U. S. 369 (2024)

Cited in the respondent’s challenge to EPA’s regulatory authority. The majority responds by grounding EPA’s labeling/registration scheme in FIFRA’s express grants (§136w(a)(1), §136a(c)(5)(B)), concluding the regulations do not exceed statutory authority. The Court does not apply any deference framework; it treats the statutory authorizations as sufficiently clear.

7) Other cited decisions (split and background)

The opinion catalogs conflicting lower-court outcomes on Roundup cancer-warning preemption, including Schaffner v. Monsanto Corp., 113 F. 4th 364 (CA3 2024) (preemption), versus Carson v. Monsanto Co., 92 F. 4th 980 (CA11 2024); Hardeman v. Monsanto Co., 997 F. 3d 941 (CA9 2021); Johnson v. Monsanto Co., 333 Ore. App. 678, 554 P. 3d 290 (2024); and Pilliod v. Monsanto Co., 67 Cal. App. 5th 591, 282 Cal. Rptr. 3d 679 (2021) (non-preemption). The Supreme Court resolves that split in favor of preemption.

The opinion also references Natural Resources Defense Council v. EPA, 38 F. 4th 34 (CA9 2022), vacating EPA’s 2020 interim registration review decision, as part of the factual/regulatory background—yet emphasizes that EPA’s repeated “not likely to cause cancer” conclusions have led to no cancer-warning requirement on Roundup’s label.

8) The Thomas concurrence’s constitutional citations

Justice Thomas concurs in the preemption holding but flags constitutional doubts about FIFRA’s scope and administration, citing United States v. Lopez, 514 U. S. 549 (T HOMAS, J., concurring), Ruckelshaus v. Monsanto Co., 467 U. S. 986, and Learning Resources, Inc. v. Trump, 607 U. S. 229 (T HOMAS, J., dissenting), as well as his discussion in Wyeth v. Levine, 555 U. S. 555 (T HOMAS, J., concurring in judgment). While not controlling, the concurrence signals possible future challenges aimed at Commerce Clause limits, nondelegation, and the constitutional footing for “administrative preemption.”

B. Legal Reasoning

The majority’s reasoning is a three-step syllogism grounded in text and regulatory mechanics:

1. State tort duties are “requirements for labeling.” Under Bates v. Dow Agrosciences LLC, failure-to-warn duties set a labeling standard and therefore count as “requirements.”
2. Federal law “requires” the EPA-approved label. EPA must approve the label at registration and must determine it contains necessary and adequate health/environment warnings and is not false or misleading (7 U. S. C. §§136a(c)(5)(B), 136(q)(1)(A), (G)). After approval, EPA regulations require the manufacturer to use that label unless EPA approves or requires changes (40 CFR §§152.44(a), 156.70(c)), with potential civil/criminal penalties for misbranding (7 U. S. C. §§136l, 136j(a)(1)(E)).
3. A state verdict compelling a cancer warning is “in addition to or different from” federal requirements. Because EPA has not required a cancer warning for glyphosate-based pesticide labels (and Roundup’s EPA-approved label lacks one), a Missouri tort duty to add such a warning would create a non-uniform labeling requirement barred by §136v(b).

Key moves and rejected counterarguments

• High-level “parallel standard” framing rejected. The Court says it is too general to claim Missouri merely demands “adequate warnings” just as FIFRA does; EPA’s registration and label-approval determinations are the operative, specific federal content-setting decisions.
• EPA’s authority upheld. FIFRA expressly empowers EPA to issue regulations and requires EPA to determine that labeling complies with FIFRA (§§136w(a)(1), 136a(c)(5)(B)).
• §136a(f)(2) does not defeat preemption. The Court reads §136a(f)(2) (registration not a defense to “any offense under” FIFRA) as about EPA enforcement and not about state tort suits; additionally, Monsanto relies not on mere “registration” but on EPA’s specific determination that cancer warnings are not required for glyphosate labels. The Court also treats Riegel as foreclosing the idea that an agency’s ability to reconsider approval eliminates preemptive “requirements.”
• “Regulatory lag” addressed institutionally, not by state tort labeling mandates. The opinion stresses FIFRA’s post-registration mechanisms—manufacturer reporting duties, EPA data calls, petitions, judicial review, and cancellation/suspension authority—as the proper way to update warnings.

C. Impact

1) Immediate effect on glyphosate/Roundup litigation

The decision substantially narrows (and in many jurisdictions will end) state-law failure-to-warn claims that hinge on the absence of a cancer warning on EPA-approved glyphosate labels. Plaintiffs will likely pivot to: (i) non-labeling theories (where viable under state law), (ii) claims framed to avoid imposing additional label content, or (iii) administrative petitions urging EPA to require new warnings.

2) Broader FIFRA preemption landscape

The Court’s central doctrinal development is its explicit characterization of EPA’s registration and label-approval determinations as federal “requirements” “under” FIFRA for §136v(b) purposes, aligning FIFRA with the agency-approval preemption logic of Riegel v. Medtronic, Inc.. This strengthens uniform, nationally consistent pesticide warning labels and shifts disputes about warning adequacy toward EPA processes rather than state juries.

3) Spillover to other statutes with similar clauses

The majority itself highlights that “several other federal statutes across a range of industries” contain similar labeling preemption provisions. Litigants can be expected to cite Monsanto Co. v. Durnell alongside Riegel when arguing that agency approvals create preemptive “requirements” even where statutory text focuses on uniform labeling.

4) Federalism and the “Uniformity” bargain

The decision confirms that FIFRA leaves States room to “regulate the sale or use” of pesticides (7 U. S. C. §136v(a))—including potentially banning them—while sharply limiting state influence over label content through tort law. Practically, the state regulatory lever becomes ex ante control over availability and use, not ex post damages suits that functionally rewrite federal labels.

5) Signals for future constitutional and administrative challenges

Justice Thomas’s concurrence, though not adopted by the Court, flags litigation trajectories attacking FIFRA’s breadth under the Commerce Clause and raising nondelegation and “administrative preemption” concerns. These critiques do not alter the holding, but they frame FIFRA as a potential vehicle for broader constitutional tests of modern regulatory structure.

4. Complex Concepts Simplified

5. Conclusion

Monsanto Co. v. Durnell establishes a clear preemption rule: when EPA has approved a pesticide label and federal law requires the manufacturer to use that label, a state failure-to-warn claim that would require adding a cancer warning is expressly preempted by FIFRA’s “Uniformity” clause (7 U. S. C. §136v(b)).

The decision’s doctrinal centerpiece is its treatment of EPA’s registration and label-approval determinations as federal “requirements” “under” FIFRA, reinforced by the analogy to Riegel v. Medtronic, Inc.. Going forward, disputes about whether pesticides require additional cancer warnings are channeled primarily into EPA’s administrative processes (and judicial review thereof), rather than state tort verdicts that would compel label changes.